专业监测看板

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

药物 / 成分：Dose Level -1、Dose Level 1 (starting dose level)、Dose Level 2、Dose Level 3

登记的停止原因（原文）：The study was revised into two separate protocols to separate treatments. We will submit as separate studies.

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

药物 / 成分：Biospecimen Collection、Cemiplimab、Cetuximab Sarotalocan Sodium、Computed Tomography

登记的停止原因（原文）：Lack of funding

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

药物 / 成分：Chronocort®、Standard Care

登记的停止原因（原文）：Protocol re-design required following EU Phase III results

A Clinical Study of V540A in Healthy Female Participants (V540A-005)

药物 / 成分：V540A-2、V540A-3、GARDASIL®9

登记的停止原因（原文）：Business Reasons

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

药物 / 成分：Arm 1 cemiplimab、Arm 2 cemiplimab and fianlimab

登记的停止原因（原文）：The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication.

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

药物 / 成分：Allogeneic Hematopoietic Stem Cell Transplantation、Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10、Cyclophosphamide、Fludarabine Phosphate

登记的停止原因（原文）：Study withdrawn before opening to accrual.

Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older

药物 / 成分：PTX-COVID19-B、Comirnaty®

登记的停止原因（原文）：The development of this product is terminated.

A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate

药物 / 成分：SUM-101、CHMI、Verorab®

登记的停止原因（原文）：Not enough resources

Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer

药物 / 成分：S-531011、HD-XRT

登记的停止原因（原文）：0 participants

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

药物 / 成分：SOC+ BSB-2002、SOC+BSB-2002

登记的停止原因（原文）：Company Decision

Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS

药物 / 成分：Naftopidil、Tamsulosin

REVERSE-Long COVID-19 With Baricitinib Study

药物 / 成分：Baricitinib 4 MG、Placebo

登记的停止原因（原文）：This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot.

1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam

药物 / 成分：Isoniazid、Rifapentine、Rifampicin

登记的停止原因（原文）：Lack of Rifapentine

Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy

药物 / 成分：glenzocimab、placebo

登记的停止原因（原文）：The study was discontinued following the cessation of the company's activities, which resulted in the investigational medicinal product no longer being available.

Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)

药物 / 成分：Hydroxychloroquine Sulfate、Hydroxychloroquine Sulfate + Azythromycin

登记的停止原因（原文）：This study was canceled before enrollment due to a decision by the Sponsor

Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease

药物 / 成分：APSLXR

登记的停止原因（原文）：Cancelled by Sponsor

Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual

药物 / 成分：Buprenorphine SL、Telehealth、In-person treatment as usual

登记的停止原因（原文）：Due to a federally mandated, institution-wide pause in research activities under the institution's Federal Wide Assurance (FWA) that occurred during the timeline for this study, recruitment was never initiated and no participants were enrolled.

A Study of LY3526318 in Healthy Male Japanese Participants

药物 / 成分：LY3526318、Placebo、Iohexol、Simvastatin

登记的停止原因（原文）：The sponsor made a business decision to withdraw the trial.

Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

药物 / 成分：Volenrelaxin、Placebo

登记的停止原因（原文）：Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart failure study that demonstrated no benefit in an overlapping patient group.

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

药物 / 成分：Antihistamine、Placebo

登记的停止原因（原文）：no funding for clinical research space